Insights - PDS Bio dropped 40% on the ASCO presentation after there were confusion around their confirmed/unconfirmed response rate. The company held a conference call (read transcript here) … Continue Reading
Premium: Read NowInsights - A few insights/notes from the ASCO abstracts that were released Thursday afternoon. ADCs Stay Winning ELEV’s ADC Validating Claudin18.2 TargetThe biggest mover from ASCO abstract release seems … Continue Reading
Premium: Read NowInsights - Biotech is bouncing back from the FTC news that raised concerns over M&A activity (read details here). Today, weight loss names are in the spotlight and … Continue Reading
Read NowInsights - The biotech rally has been put on pause on news of the FTC lawsuit to block Amgen’s (AMGN) acquisition of Horizon (HZNP). Investors are now … Continue Reading
Read NowInsights - Eli Lilly (LLY) lifted the bio market yesterday after their amyloid targeting therapy, donanemab, showed that it slowed cognitive and functional decline in a Phase … Continue Reading
Premium: Read NowInsights - 2023 has already brought several high-profile M&A deals, as pharma giants are sitting on an estimated $272B of cash and looking to spend it. As … Continue Reading
Premium: Read NowInsights - There are early signs that private money in biotech is being accumulated but sitting on the sidelines waiting to be deployed. Q1 2023 was the … Continue Reading
Read Now
